Nautilus Biotechnology (NAUT) Return on Equity (2021)

Nautilus Biotechnology's (NAUT) quarterly Return on Equity came in at 0.0% in Q4 2021, up 21.75% quarter-over-quarter from 0.0% in Q3 2021.

Nautilus Biotechnology (NAUT) Return on Equity (2021) Analysis & Trends

Nautilus Biotechnology has disclosed Return on Equity across 1 years of filings, most recently posting 0.0% for Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROE (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-0.81%
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-0.04%
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	0.00%
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-0.01%
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	0.00%
9	Abivax	91.71 Bn	91.71 Bn	-	-0.01%
10	Nautilus Biotechnology	289.99 Mn	194.12 Mn	-	-

Download Data